natgillin/translations-raw huggingface dataset:
Cosmetic use according to any one of Claims 6 to 9, characterised in that the said emulsifier is selected from the group comprising sorbitans, ethoxylated long-chain alcohols, alkyl polyglycosides, soaps, alkyl sulfates, monoalkyl and dialkyl phosphates, alkyl suffocates, hydrogenated castor oil, acyl isothionates, saccharose esters, betaine, lecithin, quaternary ammonium salts, alkyl oleates, glycerides and olive oil emulsifiers. 
Kozmetička upotreba prema bilo kojem zahtjevu od 6 do 9, naznačena time da se navedeni emulgator bira iz skupine koja sadrži sorbitane, etoksilirane dugolančane alkohole, alkil poliglikozide, sapune, alkil sulfate, monoalkil i dialkil fosfate, alkil sulfonate, hidrogenizirana ricinusova ulja, acil izotionate, saharozne estere, betain, lecitin, kvartarne amonijeve soli, alkil oleate, gliceridi i emulgatore maslinovog ulja.
Cosmetic use according to any one of Claims 6 to 9, characterised in that the said emollient is selected from the group comprising ianolin, almond oil, olive oil, hydrogenated castor oil, microcrystalline wax, polydimethylsiloxane (dimethicone), polymethylphenylsiloxane, polymers of glycol and silicone, mineral oils, paraffin, ozokerite, ceresine, triglyceride esters, monoglyceride acetylates, ethoxylated glycerides, alkyl esters of fatty acids, fatty acids, long-chain alcohols, sterols, beeswax, polyhydric alcohols, polyesters, and fatty acid amides. 
Kozmetička upotreba prema bilo kojem zahtjevu od 6 do 9, naznačena time da se navedeno omekšavajuće sredstvo bira iz skupine koja sadrži ianolin, bademovo ulje, maslinovo ulje, hidrogenizirano ricinusovo ulje, mikrokristalni vosak, polidimetilsiloksan (dimetikon), polimetilfenilsiloksan polimere glikola i silikona, mineralna ulja, parafine, ozokerit, cerezin, triglicerid estere, monoglicerid, acetilate, etoksilirane gliceride, alkilne estere masnih kiselina, masne kiseline, dugolančane alkohole, sterole, pčelinji vosak, polihidroksilne alkohole, poliestere, i amide masnih kiselina.
Cosmetic use according to any one of Claims 6 to 9, characterised in that the said preservative is selected from the group comprising alcohols such as ethanol, phenoxyethanol and benzyl alcohol, methyl and propyl parahydroxy benzoate, hydroxyanisole butylate (BHA), sorbates, urea derivates, and isothiazolinones. 
Kozmetička upotreba prema bilo kojem zahtjevu od 6 do 9, naznačena time da se spomenuti konzervans bira iz skupine koja sadrži alkohole kao što su: etanol, fenoksietanol i benzil alkohol, metil i propil parahidroksi benzoat, butilhidroksianisol (BHA), sorbat, derivat uree, i izotiazolinon.
Cartridge (1) according to any one of the preceding claims, characterised in that respective filters (31, 21) in nonwoven fabric or other material are provided inside said membranes (30,20). 
Kapsula (1) prema bilo kojem od prethodnih zahtjeva, naznačena time što se odgovarajući filteri (31, 21) od netkanog materijala ili drugog materijala nalaze unutar spomenutih membrana (30, 20).
Cartridge (1) according to any one of the preceding claims, wherein said plastic films (33, 23) are coupled to the respective aluminium films (32, 22) through lamination by means of a respective layer of adhesive or other system. 
Kapsula (1) prema bilo kojem od prethodnih zahtjeva, pri čemu su spomenuti plastični filmovi (33, 23) spojeni sa odgovarajućim aluminijskim filmovima (32, 22) laminiranjem odgovarajućeg sloja adheziva ili drugim sustavom.
denotes a hydrogen or a C1 to C4 straight or branched alkyl group; 
predstavlja vodik ili C1 do C4 ravnu ili razgranatu alkilnu skupinu;
denotes a hydrogen atom, a formyl moiety or an acetyl moiety; and each R independently is the same or different and denote a triiodinated phenyl group further substituted by two groups R2 wherein each R2 is the same or different and denotes a hydrogen atom or a non-ionic hydrophilic moiety, provided that at least one R2 group in the compound of formula (I) is a hydrophilic moiety. 
predstavlja atom vodika, formil ili acetil; i svaki R je nezavisno jednak ili različit i predstavlja fenilnu skupinu s tri joda, nadalje supstituiranu sa dvije skupine R2 gdje je svaki R2 jednak ili različit i predstavlja atom vodika ili ne-ionski hidrofilni dio, uz uvjet da je barem jedna R2 skupina u spoju formule (I) hidrofilni dio.
A compound as claimed in claim 1 wherein X denotes a straight C3 to C8 alkylene chain substituted by one to six -OR1 groups. 
Spoj prema zahtjevu 1 gdje X predstavlja ravni C3 do C8 alkilenski lanac supstituiran jednom do šest -OR1 skupina.
A compound as claimed in claim 1 or 2 wherein R1 denotes a hydrogen atom or a methyl group. 
Spoj prema zahtjevu 1 ili 2 gdje R1 predstavlja atom vodika ili metilnu skupinu.
A compound as claimed in any of the preceding claims wherein X denotes a straight C3 to C5 alkylene chain having at least one hydroxyl group substituted in a position that is not vicinal to the bridge nitrogen atom. 
Spoj prema bilo kojem od prethodnih zahtjeva gdje X predstavlja ravni C3 do C5 alkilenski lanac s barem jednom hidroksilnom skupinom supstituiran na položaju koji nije susjedan veznom atomu dušika.
A compound as claimed in claim 9 wherein all R2 groups denote the entity -CONH-CH2-CHOH-CH2-OH. 
N(COCH2OH)2 Spoj prema zahtjevu 9 gdje sve R2 skupine predstavljaju dio -CONH-CH2-CHOH-CH2-OH.
Amisulpride for use in the therapy of a condition which is chemotherapy-induced nausea and vomiting. 
Amisulprid za uporabu u liječenju stanja koje je mučnina i povraćanje izazvano kemoterapijom.
Amisulpride for use in the therapy of opioid-induced nausea and vomiting. 
Amisulprid za uporabu u liječenju stanja koje je mučnina i povraćanje izazvano kemoterapijom.
Amisulpride for use in the therapy of opiate-induced nausea, vomiting and retches. 
Amisulprid za uporabu u liječenju post-operativne mučnine i povraćanja.
Amisulpride for use according to claim 1, wherein the opiate is morphine. 
Amisulprid za uporabu prema zahtjevu 1, gdje liječeni bolesnik također dobiva i opijat.
Use according claim 11, wherein said agent is used or administered in a clinically relevant amount. 
Uporaba u skladu s patentnim zahtjevom 11, pri čemu je navedena tvar korištena ili dana u klinički značajnoj količini.
A pharmaceutical composition comprising an agent according to any of claims 1-6 and at least one pharmaceutically acceptable carrier or exipient. 
Farmaceutski sastav sadrži tvar u skladu s bilo kojim od patentnih zahtjeva 1-6 i najmanje jedan farmaceutski prihvatljivi nosač ili ekscipijens.
The composition of claim 5, wherein said excipient is a solvent, such as sterile water. 
Pripravak u skladu s patentnim zahtjevom 5, naznačen time što je navedena pomoćna tvar otapalo, poput sterile water.
The composition of claim 5, wherein said excipient is a preservative, such as benzyl alcohol. 
Pripravak u skladu s patentnim zahtjevom 5, naznačen time što je navedena pomoćna tvar konzervans, poput benzil-alkohola.
A composition for use according to any preceding claim, wherein the treatment is treatment of a subject with a baseline serum alkaline phosphatase (S-ALP) level of about 200 IU/L or greater prior to treatment. 
Pripravak koji sadrži degareliks za uporabo u liječenju metastatskog stadija raka prostate u subjektu koji ima osnovnu razinu seruma alkalne fosfataze (S-ALP) od 200 IU/L ili više (prije liječenja).
Use in vitro of an indicating agent in evaluating mental conditions selected from the group consisting of mental fatigue, physical fatigue, stress, anxiety, depression and schizophrenia, which indicating agent comprises at least eight kinds of cytokines selected from the group consisting of IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-γ, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1β, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-β, neurotrophin 5, MCP-3, β-2-microglobulin, angiotensin II, CSF-3, CXC chemokine ligand 1, CXC chemokine ligand 5 and HGF, wherein the amount of each cytokine is multiplied by a weighting coefficient. 
Uporaba in vitro indikacijskog sredstva za vrednovanje mentalnih stanja, naznačena time, da su ta stanja odabrana iz skupine koju čine: mentalna iscrpljenost, fizička iscrpljenost, stres, anksioznost, depresija i shizofrenija, pri čemu indikacijsko sredstvo sadrži najmanje osam vrsta citokina odabranih iz skupine koju čine: IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, eotaksin, osnovni FGF, G-CSF, GM-CSF, IFN-γ, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1β, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-β, neurotrofin 5, MCP-3, β-2-mikroglobulin, angiotenzin II, CSF-3, CXC ligand kemokina l, CXC ligand kemokina 5 i HGF, gdje je količina svakog citokina pomnožena s koeficijentom faktora težine.
Use in vitro of a test agent in testing mental conditions, which mental conditions are selected from the group consisting of mental fatigue, physical fatigue, stress, anxiety, depression and schizophrenia, which test agent comprises at least eight kinds of antibodies selected from the group consisting of antibodies specifically recognizing IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-γ, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1β, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-β, neurotrophin 5, MCP-3, β-2-microglobulin, angiotensin II, CSF-3, CXC chemokine ligand 1, CXC chemokine ligand 5 and HGF, respectively. 
Uporaba in vitro ispitnog sredstva za testiranje mentalnih stanja, naznačena time, da su ta stanja odabrana iz skupine koju čine: mentalna iscrpljenost, fizička iscrpljenost, stres, anksioznost, depresija i shizofrenija, pri čemu ispitno sredstvo sadrži najmanje osam vrsta protutijela odabranih iz skupine protutijela koja specifično prepoznaju svakog dotičnog prema sljedećem popisu: IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, eotaksin, osnovni FGF, G-CSF, GM-CSF, IFN-γ, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1β, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-β, neurotrofin 5, MCP-3, β-2-mikroglobulin, angiotenzin II, CSF-3, CXC ligand kemokina l, CXC ligand kemokina 5 i HGF.
The method of claim 3, wherein the aforementioned biological sample is plasma, serum, saliva or urine. 
Postupak prema zahtjevu 3, naznačen time, da se prilikom gore navedenog biološkog ispitivanja radi o uzorku plazme, seruma, sline ili urina.
A composition comprising degarelix for use in the treatment of metastatic stage prostate cancer in a subject identified as having a baseline serum alkaline phosphatase (S-ALP) level of 200 IU/L or greater (prior to treatment). 
Pripravak koji sadrži degareliks za uporabo u liječenju metastatskog stadija raka prostate u subjektu koji ima osnovnu razinu seruma alkalne fosfataze (S-ALP) od 200 IU/L ili više (prije liječenja).
housing the poultry in a heated poultry shed; 
smještaj peradi u grijanoj nastambi za perad;
characterised in that, the step of thermally treating the poultry litter comprises combusting the poultry litter in a fluidised bed unit. 
naznačeno time, što korak termičke obrade otpada od peradi obuhvaća spaljivanje otpada od peradi u jedinici s fluidiziranim slojem.
A process as claimed in claim 1 in which the poultry litter is thermally treated at a temperature of the order of 850°C for at least two seconds. 
Postupak prema zahtjevu 1 gdje se otpad od peradi termički obrađuje na temperaturi u vrijednosti od 850°C najmanje dvije sekunde.
A process as claimed in claim 4 in which the heated liquid is delivered to a radiator element. 
Postupak prema zahtjevu 4 gdje se zagrijana tekućina dovodi do radijatora.
A process as claimed in claim 5 in which the heated liquid is delivered to the radiator element located inside the poultry shed. 
Postupak prema zahtjevu 5 gdje se zagrijana tekućina dovodi do radijatora koji se nalazi unutar nastambe za perad.
A process as claimed in claim 5 or 6 in which air is drawn over the radiator element and heated air is distributed inside the poultry shed. 
Postupak prema zahtjevu 5 ili 6 gdje zrak ide preko radijatora i zagrijani zrak se raspoređuje unutar nastambe za perad.
A process as claimed in claims 5 to 9 comprising the step of monitoring the temperature in the poultry shed and controlling the temperature of the environment in the poultry shed by regulating the flow of heated liquid to the radiator element. 
Postupak prema zahtjevima 5 do 9 koji obuhvaća korak praćenja temperature u nastambi za perad i kontrole okolne temperature u nastambi za perad tako što se regulira protok zagrijane tekućine do radijatora.
A process as claimed in claims 4 to 10 in which the heated liquid is heated to a temperature of the order of 85°C. 
Postupak prema zahtjevima 4 do 10 gdje se zagrijana tekućina zagrijava na temperaturu vrijednosti 85°C.
An absorbent component for a wound dressing, the component comprising a wound contacting layer comprising gel forming fibres bound to a foam layer, wherein the foam layer is bound directly to the wound contact layer by an adhesive, polymer based melt layer, by flame lamination or by ultrasound. 
Upijajuća komponenta za zavoj za ranu, gdje se komponenta sastoji od sloja u kontaktu s ranom koji sadrži vlakna koja stvaraju gel vezana na pjenasti sloj, naznačena time da je pjenasti sloj vezan izravno na sloj u kontaktu s ranom pomoću adheziva, topljivog sloja na bazi polimera, laminiranjem plamenom ili ultrazvučno.
An absorbent component for a wound dressing as claimed in claim 1, wherein the absorbent component is in sheet form. 
Upijajuća komponenta za zavoj za ranu prema zahtjevu 1, naznačena time da je upijajuća komponenta u obliku listova.
An absorbent component for a wound dressing as claimed in claim 1 or claim 2, wherein the wound contacting layer comprises a layer of woven or non-woven or knitted gel forming fibres. 
Upijajuća komponenta za zavoj za ranu prema zahtjevu 1 ili zahtjevu 2, naznačena time da sloj u kontaktu s ranom sadrži sloj tkanih ili ne-tkanih ili pletenih vlakana koja stvaraju gel.
A wound dressing as claimed in claim 6 wherein the component forms an island in direct contact with the wound surrounded by periphery of adhesive that adheres the dressing to the wound. 
Zavoj za ranu prema zahtjevu 6 naznačen time da komponenta tvori otok u izravnom kontaktu sa ranom, koji je po rubu okružen adhezivom pomoću kojeg zavoj prianja na ranu
A wound dressing as claimed in claims 6 to 8 wherein the dressing is covered by a film layer on the surface of the dressing furthest from the wound. 
Zavoj za ranu prema zahtjevima 6 do 8 naznačen time da je zavoj na površini zavoja koja je najudaljenija od rane, prekriven slojem filma.
GLYX-13 for use as in claim 1, wherein said depression is selected from the group consisting of major depressive disorder, dysthymic disorder, psychotic depression, postpartum depression, seasonal affective disorder, bipolar disorder, mood disorder, depressions caused by chronic medical conditions such as cancer or chronic pain, chemotherapy, chronic stress, post traumatic stress disorders, and manic depressive disorder. 
GLYX-13 za uporabu, u skladu sa zahtjevom 1, naznačen time da je depresija izabrana iz grupe koju čine velika depresija, melankolična depresija, psihotična depresija, postporođajna depresija, sezonski poremećaj raspoloženja, bipolarni poremećaj, poremećaj raspoloženja, depresija uzrokovana kroničnim medicinskim stanjem, kao što su kancer, kronična bol ili kemoterapija, kronični stres, posttraumatski stresni poremećaj i manično-depresivni poremećaj.
GLYX-13 for use as in any one of claims 1 to 4, wherein the treatment-resistant patient is identified as one who has been treated with at least two types of antidepressant treatments prior to administration of GLYX-13. 
GLYX-13 za primjenu u skladu sa bilo kojim od zahtjeva 1 do 4, naznačeno time da se pacijent rezistentan na terapiju definira kao pacijent koji je primio terapiju najmanje dva tipa anti depresivna tretmana prije primjene GLYX-13.
GLYX-13 for use as in claim 5, wherein the treatment-resistant patient is identified as one who is unwilling or unable to tolerate a side effect of at least one type of antidepressant treatment. 
GLYX-13 za primjenu u skladu sa zahtjevom 5, naznačeno time da je pacijent rezistentan na terapiju pacijent koji ne želi ili ne može tolerirati sporedne efekte najmanje jednog tipa antidepresivnog tretmana.
Use of GLYX-13 in the manufacture of a medicament for the treatment of refractory depression in a treatment-resistant patient in need thereof, wherein GLYX-13 is to be administered to said patient, whereby said patient is substantially relieved of at least one symptom within about 14 days. 
Primjena GLYX-13 u proizvodnji medikamenata za terapiju refraktorne depresije u terapiji rezistentnih pacijenata kojima je terapija potrebna, naznačeno time da GLYX- 13, administriran takvom pacijentu, dovodi do značajnog ublažavanja najmanje jednog simptoma tokom 14 dana.
A combination comprising as component(s): 
Kombinacija naznačena time da kao komponentu(e) sadrži:
A process for the preparation of a compound of formula (I): or a tautomer, stereoisomer, or a pharmacologically acceptable salt of any of the foregoing, wherein: 
Postupak za pripremu spoja čija je formula (I): [image] ili tautomera, stereoizomera ili neke farmakološki prihvatljive soli bilo kojeg od prije navedenih gdje je
is chosen from hydrogen atom, or an alkyl(C1-4) group, optionally substituted with one to three fluoro atoms or an hydroxy group, 
je odabran iz atoma vodika ili jedne skupine alkil(C1-4), opcionalno supstituirane jednim do tri atoma fluora ili jednom hidroksi skupinom,
reacting the obtained compound of formula (IIIa) or (IIIb), with an alkylating reagent of general formula Rx-L, wherein Rx represents a linear (C1-8)-alkyl group and L represents a 'leaving group', to give a compound of formula (IV): 
reakcija dobivenog spoja čija je formula (IIIa) ili (IIIb), s nekim alkilirajućim reagensom opće formule Rx-L, gdje Rx predstavlja linearnu (C1-8)-alkil skupinu a L predstavlja ’odlazeću skupinu’,da bi se dobio spoj čija je formula (IV):
reacting the obtained compound of formula (IV) with a sulfonamide derivative of formula R7SO2NH2, wherein R7 has the meaning given above, to give a compound of formula (I): 
reakcija dobivenog spoja čija je formula (IV) s nekim derivatom sulfonamida čija je formula R7SO2NH2, gdje R7 ima značenje koje je gore navedeno, da bi se dobio spoj čija je formula (I):
isolating the compound of formula (I) from the reaction mixture. 
izolacija spoja čija je formula (I) iz reakcijske mješavine.
A process as claimed in claim 1, for the preparation of a compound of formula (I), wherein: 
Postupak prema zahtjevu 1, za pripremu spoja čija je formula (I), naznačen time:
A compound of the general formula (I) wherein V is selected from the group consisting of S, SO2, SO, O and NH; 
Tvar opće formule (I) [image] pri čemu V je odabran iz grupe koja se sastoji od S, SO2, SO, O i NH;
is selected from the group consisting of F, Cl, Br, I, CH2Y, CHY2 and CY3, wherein Y is a halogen atom; and R9 and R10 together with the carbon atom to which they are attached form an optionally substituted C3-6-cycloalkyl or C3-6- heterocyclyl, preferably a nitrogen-containing optionally substituted heterocyclyl; 
je odabran iz grupe koja se sastoji od F, Cl, Br, I, CH2Y, CHY2 i CY3, gdje je Y atom halogena; i R9 i R10 zajedno s atomom ugljika za koji su povezani tvore C3-6-cikloalkil ili C3-6-heterociklil, poželjno heterociklil koji sadrži dušik;
as well as salts thereof. 
kao i njihove soli.
Compound according to any of claims 1-3, wherein R9 and R10 together with the carbon atom to which they are attached form an optionally substituted piperidinyl or piperazinyl, preferably an optionally substituted piperidinyl. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu R9 i R10 zajedno s atomom ugljika za kojeg su vezani tvore piperidinil ili piperazinil, poželjno piperidinil.
Compound according to any of claims 1-4, wherein R9 and R10 together with the carbon atom to which they are attached form an optionally substituted nitrogen-containing heteroaryl or optionally substituted heterocyclyl wherein the nitrogen atom is separated by two carbon atoms from the carbon atom to which R9 and R10 are attached. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1-4, pri čemu R9 i R10 zajedno s atomom ugljika za kojeg su vezani tvore heteroaril ili heterociklil koji sadrži dušik gdje je atom dušika odvojen dvjema atomima ugljika od atoma ugljika za koji su R9 i R10 vezani.
A compound of the general formula Wherein; V is selected from the group consisting of S, SO2, SO, O and NH; 
Tvar opće formule [image] pri čemu V je odabran iz grupe koja se sastoji od S, SO2, SO, O i NH;
Use according claim 11, wherein said compound is used or administered in a clinically relevant amount. 
Uporaba u skladu s patentnim zahtjevom 11, pri čemu je navedena tvar korištena ili dana u klinički značajnoj količini.
A pharmaceutical composition comprising a compound according to any of claims 1-6 and at least one pharmaceutically acceptable carrier or excipient. 
Farmaceutski sastav sadrži tvar u skladu s bilo kojim od patentnih zahtjeva 1-6 i najmanje jedan farmaceutski prihvatljivi nosač ili ekscipijens.
separating the biological sample from the immobilized capture reagents; 
odvajanje biološkog uzorka iz imobiliziranog zahvaćenog reagensa;
measuring the level of VEGF110+ bound to the capture reagents using a detection means for the detectable antibody. 
mjerenje razine VEGF110+ spojenog na zahvaćeni reagens uporabom sredstva za detekciju za otkrivajuće protutijelo.
The method of claim 1, wherein the biological sample is isolated from a human subject, optionally wherein the human subject is a vascular, diabetic, or cancer patient and the measuring step (d) further comprises a comparison with a standard curve to determine the level of VEGF compared to a normal individual. 
Postupak prema zahtjevu 2, naznačen time, da ljudski pojedinac je vaskularni pacijent, dijabetički pacijent ili pacijent koji boluje od raka, a korak (d) nadalje obuhvaća usporedbu sa standardnom krivuljom za određivanje razine VEGF u usporedbi s istom kod zdravog pojedinca.
Netupitant for use according to claim 1, wherein said netupitant occupies at least 80% of NK1 receptors in the striatum seventy-two hours after said administration. 
Kombinacija za uporabu prema patentnom zahtjevu 1 ili 2, naznačena time što navedeni netupitant zauzima najmanje 80% NK1 receptora u strijatu sedamdeset i dva sata poslije navedene primjene.
said patient is administered on day one a first dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant, wherein said first dose comprises from 50 to 70% of a minimum effective dose when administered alone; and 
na dan jedan, prva doza deksametazona koja je neefikasna protiv mučnine i povraćanja kada je primjenjena pojedinačno, ali efikasna protiv mučnine i povraćanja kada je primjenjena u kombinaciji sa navedenim netupitantom, gdje navedena prva doza sadrži od 50 do 70% minimalne efikasne doze kada se primjenjuje pojedinačno; i
a 5- to 10- membered aromatic heterocyclic ring containing 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom, other than a carbon atom, and which may be substituted with 1 to 3 substituents selected from a halogen atom, C1-6 alkyl, C1-6 alkoxy, and phenyl which may be substituted with C1-6 alkoxy; is a single bond; 
do 10- članski aromatični heterociklički prsten koji sadrži 1 do 4 hetero atoma izabrana od atoma dušika, atoma sumpora, i atoma vodika, različita od atoma ugljika, i koji može biti supstituiran sa 1 do 3 supstituenta izabrana od atoma halogena, C1-6 alkila, C1-6 alkoksija, i fenila koji može biti supstituiran sa C1-6 alkoksijem [image] je jednostruka veza;
is a hydrogen atom or C1-6 alkyl which may be substituted with a hydroxy; 
jest atom vodika ili C1-6 alkil koji može biti supstituiran sa hidroksijem;